"I was impressed by the broad scope and high quality of the applications and enjoyed the stringent and well-organized review meetings with AU faculty and industry representatives. It’s also great to see that industry partners seem to have considerable interest in the type of pre-competitive open innovation projects the ODIN initiative supports. This – together with funding that provides a reasonable runway – is essential in order to be able to design and successfully run highly innovative projects in the areas of biomarker and target validation that address real-world problems with state-of-the-art science."

says Georg Duenstl, Associate Research Fellow at LEO Pharma.

We are looking forward to announcing the exciting projects, which will be funded by ODIN. Stay tuned!